Eli Lilly Wins New Approvals for Drug Pipeline

Shares of Eli Lilly ( LLY) were up nearly 3% in early trading after the company announced approvals for Symbyax for the acute treatment of treatment-resistant depression.

The company also announced the FDA approved two new combination indications for Zyprexar (olanzapine) and fluoxetine for the acute treatment of bipolar depression and treatment resistant depression.

We recently removed LLY from our "Recommended" list on Feb. 27, when the shares were trading at $31.06. The company has a 6.02% dividend yield, based on Friday's closing stock price of $32.55.

We are watching the stock closely and are looking for further points to potentially have us add the name back on our list.

Eli Lilly is not recommended at this time, holding a Dividend.com rating of 3.4 out of 5 stars.

Tiffany & Co. Profit Drops 76%, but Adjusted Earnings Beat Street

Shares of luxury retailer Tiffany & Co. ( TIF) jumped 10% in morning trading Monday, after the company delivered a mixed earnings report in which adjusted fourth-quarter profit beat analyst expectations.

The New York City-based company said its fiscal fourth-quarter net profit was $31.1 million, or 25 cents per share, a 76% drop from the $127.4 million, or 96 cents per share, that the company earned in the year-ago period.

Not including special one-time items, such as restructuring costs and writedowns, Tiffany profited 85 cents per share, which beat the average Wall Street analyst estimate of 78 cents per share.

Overall sales for the quarter fell 20% from year-ago levels to $841.2 million. These numbers include a 34% sales decline in the quarter at Tiffany's flagship store in Manhattan.

If you liked this article you might like

Alabama Governor Sees Autos Leading Charge for High Tech Jobs

BMW Closing in on Mercedes' Luxury Auto Sales Lead in the U.S.

The Amazing 45-MPG Mercedes Sedan

Investing in Global Demand for Cars

The Tesla-Based Mercedes (as Seen Through Google Glass)